Expression of chromosomal regional maintenance protein-1 may be associated with subcellular survivin expression in human gastric and colorectal carcinoma

Shintani,Michiko; Tashiro,Akito; Sangawa,Akiko; Yamao,Naoki; Kamoshida,Shingo

doi:10.3892/ol.2016.5220

Expression of chromosomal regional maintenance protein-1 may be associated with subcellular survivin expression in human gastric and colorectal carcinoma

Authors:
- Michiko Shintani
- Akito Tashiro
- Akiko Sangawa
- Naoki Yamao
- Shingo Kamoshida
View Affiliations

Affiliations: Laboratory of Pathology, Division of Medical Biophysics, Kobe University Graduate School of Health Sciences, Kobe, Hyogo 654‑0142, Japan, Department of Diagnostic Pathology, Osaka Red Cross Hospital, Osaka 543‑8555, Japan, Department of Clinical Laboratory, Kuma Hospital, Kobe, Hyogo 650‑0011, Japan
Published online on: October 4, 2016 https://doi.org/10.3892/ol.2016.5220
Pages: 4630-4634

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Survivin, a member of the inhibitor of apoptosis protein family, is a potential prognostic marker and molecular target for anticancer therapies. Chromosomal regional maintenance protein‑1 (CRM‑1) mediates the nuclear export of proteins such as survivin. The aims of the present study were to compare the expression and subcellular localization of CRM‑1 in human gastric and colorectal carcinomas and to assess the association between CRM‑1 and survivin expression in these tumor types. The nuclear and cytoplasmic CRM‑1 expression rates in gastric carcinoma were 61% (42/69) and 29% (20/69), respectively, while the nuclear and cytoplasmic CRM‑1 expression rates in colorectal carcinoma were 55% (43/78) and 37% (29/78), respectively. Nuclear and cytoplasmic CRM‑1 expression was found to be significantly correlated with nuclear and cytoplasmic survivin expression in colorectal carcinoma, but not gastric carcinoma. These results indicate that CRM‑1 expression patterns differ between gastric and colorectal carcinomas and thus, we hypothesize that CRM‑1‑mediated nuclear export of survivin may be deregulated in gastric carcinoma. Therefore, CRM‑1 may exhibit different functions in gastric and colorectal carcinoma.

View Figures

View References

1	Li F, Ackermann EJ, Bennett CF, Rothermel AL, Plescia J, Tognin S, Villa A, Marchisio PC and Altieri DC: Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat Cell Biol. 1:461–466. 1999. View Article : Google Scholar : PubMed/NCBI
2	Li F and Ling X: Survivin study: An update of “what is the next wave”? J Cell Physiol. 208:476–486. 2006. View Article : Google Scholar : PubMed/NCBI
3	Knauer SK, Mann W and Stauber RH: Survivin's dual role: An export's view. Cell Cycle. 6:518–521. 2007. View Article : Google Scholar : PubMed/NCBI
4	Andersen MH, Svane IM, Becker JC and Straten PT: The universal character of the tumor-associated antigen survivin. Clin Cancer Res. 13:5991–5994. 2007. View Article : Google Scholar : PubMed/NCBI
5	Chen P, Li J, Ge LP, Dai CH and Li XQ: Prognostic value of survivin, X-linked inhibitor of apoptosis protein and second mitochondria-derived activator of caspases expression in advanced non-small-cell lung cancer patients. Respirology. 15:501–509. 2010. View Article : Google Scholar : PubMed/NCBI
6	Xiaoyuan C, Longbang C, Jinghua W, Xiaoxiang G, Huaicheng G, Qun Z and Haizhu S: Survivin: A potential prognostic marker and chemoradiotherapeutic target for colorectal cancer. Ir J Med Sci. 179:327–335. 2010. View Article : Google Scholar : PubMed/NCBI
7	Youssef NS, Hewedi IH and Abd Raboh NM: Immunohistochemical expression of survivin in breast carcinoma: Relationship with clinicopathological parameters, proliferation and molecular classification. J Egypt Natl Canc Inst. 20:348–357. 2008.PubMed/NCBI
8	Wang TT, Qian XP and Liu BR: Survivin: Potential role in diagnosis, prognosis and targeted therapy of gastric cancer. World J Gastroenterol. 13:2784–2790. 2007.PubMed/NCBI
9	Ito T, Shiraki K, Sugimoto K, Yamanaka T, Fujikawa K, Ito M, Takase K, Moriyama M, Kawano H, Hayashida M, et al: Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology. 31:1080–1085. 2000. View Article : Google Scholar : PubMed/NCBI
10	Mita AC, Mita MM, Nawrocki ST and Giles FJ: Survivin: Key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res. 14:5000–5005. 2008. View Article : Google Scholar : PubMed/NCBI
11	Miura K, Fujibuchi W, Ishida K, Naitoh T, Ogawa H, Ando T, Yazaki N, Watanabe K, Haneda S, Shibata C and Sasaki I: Inhibitor of apoptosis protein family as diagnostic markers and therapeutic targets of colorectal cancer. Surg Today. 41:175–182. 2011. View Article : Google Scholar : PubMed/NCBI
12	Sah NK, Khan Z, Khan GJ and Bisen PS: Structural, functional and therapeutic biology of survivin. Cancer Lett. 244:164–171. 2006. View Article : Google Scholar : PubMed/NCBI
13	Stauber RH, Mann W and Knauer SK: Nuclear and cytoplasmic survivin: Molecular mechanism, prognostic, and therapeutic potential. Cancer Res. 67:5999–6002. 2007. View Article : Google Scholar : PubMed/NCBI
14	Fornerod M, Ohno M, Yoshida M and Mattaj IW: CRM1 is an export receptor for leucine-rich nuclear export signals. Cell. 90:1051–1060. 1997. View Article : Google Scholar : PubMed/NCBI
15	Fukuda M, Asano S, Nakamura T, Adachi M, Yoshida M, Yanagida M and Nishida E: CRM1 is responsible for intracellular transport mediated by the nuclear export signal. Nature. 390:308–311. 1997. View Article : Google Scholar : PubMed/NCBI
16	Ossareh-Nazari B, Bachelerie F and Dargemont C: Evidence for a role of CRM1 in signal-mediated nuclear protein export. Science. 278:141–144. 1997. View Article : Google Scholar : PubMed/NCBI
17	Stade K, Ford CS, Guthrie C and Weis K: Exportin 1 (Crm1p) is an essential nuclear export factor. Cell. 90:1041–1050. 1997. View Article : Google Scholar : PubMed/NCBI
18	Huang WY, Yue L, Qiu WS, Wang LW, Zhou XH and Sun YJ: Prognostic value of CRM1 in pancreas cancer. Clin Invest Med. 32:E315–E321. 2009.PubMed/NCBI
19	Inoue H, Kauffman M, Shacham S, Landesman Y, Yang J, Evans CP and Weiss RH: CRM1 blockade by selective inhibitors of nuclear export attenuates kidney cancer growth. J Urol. 189:2317–2326. 2013. View Article : Google Scholar : PubMed/NCBI
20	Noske A, Weichert W, Niesporek S, Röske A, Buckendahl AC, Koch I, Sehouli J, Dietel M and Denkert C: Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer. Cancer. 112:1733–1743. 2008. View Article : Google Scholar : PubMed/NCBI
21	van der Watt PJ, Maske CP, Hendricks DT, Parker MI, Denny L, Govender D, Birrer MJ and Leaner VD: The Karyopherin proteins, Crm1 and Karyopherin beta1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation. Int J Cancer. 124:1829–1840. 2009. View Article : Google Scholar : PubMed/NCBI
22	Yang X, Cheng L, Yao L, Ren H, Zhang S, Min X, Chen X, Zhang J and Li M: Involvement of chromosome region maintenance 1 (CRM1) in the formation and progression of esophageal squamous cell carcinoma. Med Oncol. 31:1552014. View Article : Google Scholar : PubMed/NCBI
23	Zhou F, Qiu W, Yao R, Xiang J, Sun X, Liu S, Lv J and Yue L: CRM1 is a novel independent prognostic factor for the poor prognosis of gastric carcinomas. Med Oncol. 30:7262013. View Article : Google Scholar : PubMed/NCBI
24	Hama H, Tabuchi T, Ito Y, Fukushima W, Matsunaga I, Miyashiro I and Nakayama T: Smoking behavior and participation in screening for lung, gastric, and colorectal cancers. Nihon Koshu Eisei Zasshi. 63:126–134. 2016.(In Japanese). PubMed/NCBI
25	Nishimoto H, Katanoda K, Sato N, Sobue T and Mikami H: Cancer statistics in Japan 2014Wakao F: Center for Cancer Control and Information Services. National Cancer Center; 2015, (In Japanese).
26	Shintani M, Sangawa A, Yamao N and Kamoshida S: Immunohistochemical expression of nuclear and cytoplasmic survivin in gastrointestinal carcinoma. Int J Clin Exp Pathol. 6:2919–2927. 2013.PubMed/NCBI
27	Hutten S and Kehlenbach RH: CRM1-mediated nuclear export: To the pore and beyond. Trends Cell Biol. 17:193–201. 2007. View Article : Google Scholar : PubMed/NCBI
28	Knauer SK, Krämer OH, Knösel T, Engels K, Rödel F, Kovács AF, Dietmaier W, Klein-Hitpass L, Habtemichael N, Schweitzer A, et al: Nuclear export is essential for the tumor-promoting activity of survivin. FASEB J. 21:207–216. 2007. View Article : Google Scholar : PubMed/NCBI
29	Stauber RH, Rabenhorst U, Rekik A, Engels K, Bier C and Knauer SK: Nucleocytoplasmic shuttling and the biological activity of mouse survivin are regulated by an active nuclear export signal. Traffic. 7:1461–1472. 2006. View Article : Google Scholar : PubMed/NCBI
30	Japanese Gastric Cancer Association, . Japanese classification of gastric carcinoma. 3rd English edition. Gastric Cancer. 14:101–112. 2011. View Article : Google Scholar : PubMed/NCBI
31	Japanese Society for Cancer of the Colon and Rectum, . Japanese Classification of Colorectal Carcinoma. 2nd English edition. Kanehara & Co., Ltd.; Tokyo: 2009
32	Shen A, Wang Y, Zhao Y, Zou L, Sun L and Cheng C: Expression of CRM1 in human gliomas and its significance in p27 expression and clinical prognosis. Neurosurgery. 65:153–159. 2009. View Article : Google Scholar : PubMed/NCBI
33	Yao Y, Dong Y, Lin F, Zhao H, Shen Z, Chen P, Sun YJ, Tang LN and Zheng SE: The expression of CRM1 is associated with prognosis in human osteosarcoma. Oncol Rep. 21:229–235. 2009.PubMed/NCBI
34	Wang S, Han X, Wang J, Yao J and Shi Y: Antitumor effects of a novel chromosome region maintenance 1 (CRM1) inhibitor on non-small cell lung cancer cells in vitro and in mouse tumor xenografts. PLoS One. 9:e898482014. View Article : Google Scholar : PubMed/NCBI
35	Yashiroda Y and Yoshida M: Nucleo-cytoplasmic transport of proteins as a target for therapeutic drugs. Curr Med Chem. 10:741–748. 2003. View Article : Google Scholar : PubMed/NCBI
36	Zhang K, Wang M, Tamayo AT, Shacham S, Kauffman M, Lee J, Zhang L, Ou Z, Li C, Sun L, et al: Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma. Exp Hematol. 41:67–78.e4. 2013. View Article : Google Scholar : PubMed/NCBI
37	Knauer SK, Bier C, Habtemichael N and Stauber RH: The Survivin-Crm1 interaction is essential for chromosomal passenger complex localization and function. EMBO Rep. 7:1259–1265. 2006. View Article : Google Scholar : PubMed/NCBI
38	Nguyen KT, Holloway MP and Altura RA: The CRM1 nuclear export protein in normal development and disease. Int J Biochem Mol Biol. 3:137–151. 2012.PubMed/NCBI